Vnitr Lek 1997, 43(11):707-711

[The effects of Carvedilol, a beta-blocker, in experimental ischemia-reperfusion kidney injury].

J Necas, L Bartosíková, L Drápelová, K Husek, V Pavlícek, S Kuchtícková
Ustav humánní farmakologie a toxikologie FaF VFU, Brno.

Carvedilol is a recently introduced drug with multiple action with a non-selective beta-antiadrenergic and selective alpha1-antiadrenergic action used for treatment of mild to medium severe hypertension. The authors investigated in their experiments the protective effect of carvedilol under conditions of ischaemia-reperfusion of the kidney in the laboratory rat. The animals were divided into four groups 1. the control group was fed a diet without carvedilol for a period of two weeks. Groups 2, 3 and 4 were fed for two weeks a diet containing carvedilol, 1-3-10 mg/kg/day resp. After completed medication in all animals ischaemia of the kidney was induced (60 min.) with subsequent reperfusion (10 min.) Then the animals were sacrificed, the kidney was removed for histopathological examination, in blood the malondialdehyde (MDA) level was assessed. The conclusions of the investigation indicate a marked protective effect of the administered preparation. Carvedilol prevents the disintegration of tubular epithelia, pycnosis of the nuclei, and reduced the development of oedematous changes. These findings correlate with MDA levels.

Keywords: Adrenergic beta-Antagonists, pharmacology, ; Animals; Carbazoles, pharmacology, ; Carvedilol; Kidney, metabolism, ; Male; Malondialdehyde, metabolism, ; Propanolamines, pharmacology, ; Rats; Rats, Wistar; Reperfusion Injury, metabolism,

Published: November 1, 1997  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Necas J, Bartosíková L, Drápelová L, Husek K, Pavlícek V, Kuchtícková S. [The effects of Carvedilol, a beta-blocker, in experimental ischemia-reperfusion kidney injury]. Vnitr Lek. 1997;43(11):707-711.
Download citation




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.